Literature DB >> 31517639

Alcoholic Liver Disease Epidemiology in the United States: A Retrospective Analysis of 3 US Databases.

Katherine Dang1, Grishma Hirode1, Ashwani K Singal2, Vinay Sundaram3, Robert J Wong1.   

Abstract

OBJECTIVES: Alcoholic liver disease (ALD) prevalence, particularly the subset with advanced liver disease, is not well defined. Herein, we aim to provide a comprehensive assessment of ALD epidemiology across the spectrum of disease severity and across different settings using 3 unique US databases.
METHODS: We performed a retrospective, observational study of US adults with ALD using 2001-2016 National Health and Nutrition Examination Survey (NHANES), 2007-2014 Nationwide Inpatient Sample (NIS), and 2007-2017 United Network for Organ Sharing (UNOS) registry. ALD in the NHANES was defined using clinical laboratory data and self-reported alcohol use, among which fibrosis-4 score of >2.67 defined stage ≥3 fibrosis. Alcoholic cirrhosis (AC) in the NIS was identified using International Classification of Diseases, Ninth Revision codes. ALD in the UNOS was identified using UNOS coding.
RESULTS: From 2001-2002 to 2015-2016, the overall weighted ALD prevalence was stable from 8.8% to 8.1% (P = 0.102), whereas the proportion of ALD with stage ≥3 fibrosis increased from 2.2% (95% CI: 0.4-4.0) to 6.6% (95% CI: 2.0-9.9; P = 0.007) (NHANES). From 2007 to 2014, the number of hospitalizations among patients with AC per 1,000 increased by 32.8%, and the proportion of hospitalizations among the patients with AC with ≥3 cirrhosis complications increased from 11.6% in 2007 to 25.8% in 2014 (Ptrend < 0.0001) (NIS). From 2007 to 2017, the total number of adults with ALD listed for liver transplant increased by 63.4% and the proportion with concurrent hepatocellular carcinoma increased by 178% (UNOS). DISCUSSION: Among these 3 US databases, consistent observations of increasing ALD severity emphasize the urgent need for greater awareness about the consequences of unhealthy alcohol use and interventions aimed specifically at addressing alcohol use disorders.

Entities:  

Mesh:

Year:  2020        PMID: 31517639     DOI: 10.14309/ajg.0000000000000380

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  12 in total

Review 1.  Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease.

Authors:  Ashwani K Singal; Paul Kwo; Allison Kwong; Suthat Liangpunsakul; Alexandre Louvet; Pranoti Mandrekar; Craig McClain; Jessica Mellinger; Gyongyi Szabo; Norah Terrault; Mark Thursz; Gerald S Winder; W Ray Kim; Vijay H Shah
Journal:  Hepatology       Date:  2021-11-27       Impact factor: 17.298

2.  The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice.

Authors:  Huikuan Chu; Lu Jiang; Bei Gao; Nagsen Gautam; Jawaher A Alamoudi; Sonja Lang; Yanhan Wang; Yi Duan; Yazen Alnouti; Edward E Cable; Bernd Schnabl
Journal:  Transl Res       Date:  2020-06-15       Impact factor: 7.012

Review 3.  Iron overload in alcoholic liver disease: underlying mechanisms, detrimental effects, and potential therapeutic targets.

Authors:  Long-Xia Li; Fang-Fang Guo; Hong Liu; Tao Zeng
Journal:  Cell Mol Life Sci       Date:  2022-03-24       Impact factor: 9.261

Review 4.  A Review of Chronic Comorbidities in Adults Living With HIV: State of the Science.

Authors:  Allison R Webel; Julie Schexnayder; Patricia A Cioe; Julie A Zuñiga
Journal:  J Assoc Nurses AIDS Care       Date:  2021 May-Jun 01       Impact factor: 1.809

Review 5.  Hospice care for end stage liver disease in the United States.

Authors:  Eric S Orman; Amy W Johnson; Marwan Ghabril; Greg A Sachs
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2021-02-24       Impact factor: 4.095

Review 6.  Emerging Noninvasive Biomarkers, and Medical Management Strategies for Alcoholic Hepatitis: Present Understanding and Scope.

Authors:  Khushboo S Gala; Vatsalya Vatsalya
Journal:  Cells       Date:  2020-02-25       Impact factor: 6.600

Review 7.  Epidemiology of Alcohol-Associated Liver Disease.

Authors:  Sen Han; Zhihong Yang; Ting Zhang; Jing Ma; Kristina Chandler; Suthat Liangpunsakul
Journal:  Clin Liver Dis       Date:  2021-05-26       Impact factor: 6.265

8.  Changes in Serum Myostatin Levels in Alcoholic Hepatitis Correlate with Improvement in MELD.

Authors:  Hani Shamseddeen; Abhishek Madathanapalli; Vijay S Are; Vijay H Shah; Arun J Sanyal; Qing Tang; Tiebing Liang; Kayla Gelow; Teresa A Zimmers; Naga Chalasani; Archita P Desai
Journal:  Dig Dis Sci       Date:  2020-10-19       Impact factor: 3.487

9.  Ethnic Minorities and Low Socioeconomic Status Patients With Chronic Liver Disease Are at Greatest Risk of Being Uninsured.

Authors:  Kabiru Ohikere; Amit S Chitnis; Thomas A Hahambis; Ashwani Singal; Robert J Wong
Journal:  Gastroenterology Res       Date:  2021-12-21

10.  Contemporary Trends in Hospitalizations for Comorbid Chronic Liver Disease and Substance Use Disorders.

Authors:  Archita P Desai; Marion Greene; Lauren D Nephew; Eric S Orman; Marwan Ghabril; Naga Chalasani; Nir Menachemi
Journal:  Clin Transl Gastroenterol       Date:  2021-06-18       Impact factor: 4.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.